Angiotensin II Regulates Anxiety and Social-Affective Top-Down and Bottom-Up Attention Control in a Sex-dependent Manner

Authors

Mengfan Han[1,2], Kun Fu[1,2], Wenyi Dong[1,2], Junjie Wang[1,2], Dan Liu[1,2], Qian Zhuang[3], Xiaolei Xu[4], Ferraro Stefania[1,2], Ting Xu[5], Keith M Kendrick[1,2], Wing Chung Chang[6], Benjamin Becker[7]*

Affiliations

[1] The Center of Psychosomatic Medicine, Sichuan Provincial Center for Mental Health, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China
[2] MOE Key Laboratory for Neuroinformation, School of Life Science and Technology, University of Electronic Science and Technology of China, Chengdu, China
[3] Center for Cognition and Brain Disorders, The Affiliated Hospital of Hangzhou Normal University, Hangzhou, Zhejiang, China
[4] Faculty of Psychology, Shandong Normal University, Jinan, China
[5] Faculty of Psychology, Southwest University, Chongqing, China
[6] Department of Psychiatry, School of Clinical Medicine, University of Hong Kong, Hong Kong SAR, China
[7] Department of Psychology, The University of Hong Kong, Hong Kong SAR, China

Abstract

The renin-angiotensin system (RAS), traditionally known for cardiovascular regulation, has increasingly been recognized as a modulator of cognitive and affective functions. However, whether the RAS regulates attentional control and whether such effects are sex-dependent remain unexplored.

The present preregistered, randomized, double-blind, placebo-controlled pharmacological eye-tracking study (N = 79) examined the effects of transient angiotensin II type 1 receptor (AT1R) blockade via losartan (50 mg) on emotional attention control using a validated anti-saccade task with social (emotional faces) and non-social stimuli. Treatment effects on state anxiety and oculomotor responses were characterized using traditional performance metrics and a novel trial-history informed dynamic control (TIDC) framework for adaptive control.

Losartan reduced state anxiety irrespective of sex and induced sexually dimorphic reconfiguration of attentional processing. In females, AT1R blockade enhanced performance by reducing endpoint error without altering latency. Conversely, in males, losartan increased endpoint error and prolonged latency of the first correct saccade. Trial-history analyses further revealed that losartan reduced error probabilities following error and repeat trials in both sexes. Yet, following correct trials, females receiving losartan maintained lower error probabilities, while males receiving losartan exhibited higher errors, potentially reflecting a failure to flexibly disengage from the effortful controlled mode.

Findings indicate that the RAS modulates anxiety and attentional control, the latter in a sex-

dependent manner. AT1R blockade can reconfigure attentional processing and adaptive control, suggesting sex-specific therapeutic potential in disorders characterized by excessive anxiety and attentional dysregulation.

Keywords: renin-angiotensin, AT1R, Losartan, Antisaccade, attention, Emotion, Post-error adjustment, Stimulus switching, Trial-history effects, Sex differences

1 Introduction

The renin-angiotensin system (RAS) is traditionally known for its regulatory role in peripheral physiological functions, particularly cardiovascular and renal homeostasis (Jackson et al., 2018). Accumulating evidence from recent studies suggests that the RAS also regulates affective, reward-related and cognitive functions (Swiercz et al., 2020; T. Xu et al., 2024) and plays a role in neuropsychiatric disorders such as post-traumatic stress disorder (PTSD), depression, and Alzheimer's disease (Ali et al., 2024; Barthold et al., 2018; Kang et al., 2024; Wright & Harding, 2010) (overview in Xu et al., 2025). This shift not only expands our knowledge about RAS function but also provides an important perspective for exploring new treatment avenues, as pharmacological intervention targeting the RAS may improve emotion regulation and mnemonic function (Prasad et al., 2025; T. Xu et al., 2022; F. Zhou et al., 2019), offering a promising avenue for treating neuropsychiatric disorders.

Within the central RAS components effects on cognitive and affective domains are primarily mediated by the angiotensin II type 1 receptor (AT1R) (Benicky et al., 2011; T. Xu et al., 2024) with convergent evidence suggesting a role in fear- and anxiety-related domains across species. Rodent studies suggest that pharmacological blockade of the AT1R enhances regulation of fear (Chrissobolis et al., 2020; Swiercz et al., 2020; Yang et al., 2023) whereas the administration of angiotensin II induced anxiety-like behavior, as evidenced by reduced time spent in the center of the open field test and decreased time spent in the open arms of the elevated plus maze (Duchemin et al., 2013; Gao et al., 2021).

Human studies have combined transient pharmacological AT1R blockade via losartan – a selective competitive antagonist of the AT1R - with behavioral paradigms and functional Magnetic Resonance Imaging (fMRI) to examine a corresponding role in humans. Results indicate that losartan decreases amygdala reactivity in high-trait anxious individuals (Reinecke et al., 2018) and enhances fear extinction and implicit fear regulation via strengthening prefrontal control over the amygdala (Zhang et al., 2023; F. Zhou et al., 2019). The beneficial effects on prefrontal cortex regulatory control of acute administration protocols are flanked by preclinical and clinical evidence suggesting that AT1R blockade enhances synaptic plasticity and reduces oxidative stress in the prefrontal cortex (Benicky et al., 2011; Sharifi et al., 2019) and that long-term use may reduce dementia-related cognitive decline and prevent PTSD symptoms (Barthold et al., 2018; Khoury et al., 2012; Seligowski et al., 2021).

Attentional control, referring to the ability to suppress distracting information and focus on task-relevant information plays a central role in frontal cortex-dependent emotion regulation and

cognitive control (Diamond, 2013; Feng et al., 2018; Li et al., 2020; Peers & Lawrence, 2009). Deficits in this domain, in particular a disrupted balance between top-down attention regulation processes and bottom-up stimulus-driven processes and in turn an inappropriate allocation of attentional resources, particularly excessive focus on threat-related information, represent neurocognitive candidate pathomechanisms for the development and maintenance of anxiety and trauma-related disorders (Bishop, 2009; Cisler & Koster, 2010). However, despite increasing evidence for a potential role of the RAS in the pathogenesis and treatment of these disorders (Prasad et al., 2025; Seligowski et al., 2021; Zhang et al., 2023) its regulatory role in attentional control of salient affective stimuli has not been examined.

Bottom-up and top-down attentional control, as well as the impact of pathology-relevant dysregulations and pharmacological modulation can be reliably measured by assessing eye gaze in the pro-saccade and anti-saccade paradigm (Hutton & Ettinger, 2006; Zhuang, Zheng, et al., 2021). This paradigm requires participants to suppress automatic reflexive eye movements towards a stimulus (bottom-up process, pro-saccade), while explicitly initiating eye movement in the opposite direction (top-down process, anti-saccade) (Munoz & Everling, 2004). In line with previous studies examining neurotransmitter and neuropeptide regulation of bottom-up and top-down affective attention regulation (Cameron et al., 2018; Zhuang, Zheng, et al., 2021), we here combined a pre-registered randomized double-blind placebo-controlled design with a social-affective pro-saccade anti-saccade task in a pharmacological eye-tracking study employing a selective and competitive AT1R blocker (Losartan).

To determine the effects of transient AT1R blockade, we focused on three key oculomotor metrics derived from the first saccade: (1) Direction error rate - the failure to suppress reflexive saccades toward the target, which is considered a direct measure of top-down inhibition (Munoz & Everling, 2004); (2) Saccadic latency - the time from stimulus onset to initiation of a correct directional saccade, reflecting processing and response speed (Noorani & Carpenter, 2016); and (3) Endpoint error - the spatial accuracy of correct saccades, quantified as the distance between the landing position and the target, indicating movement precision (Kanaan & Moacdieh, 2022). Together, these metrics evaluate the entire process from the higher-order cognitive outcome (successful inhibition) to the quality of the motor output (speed and precision). Based on previous studies indicating a role of the AT1R in predictive processing and adaptive prefrontal regulation (Han et al., 2025; T. Xu et al., 2023, 2024; F. Zhou et al., 2019), we hypothesized that its blockade would enhance inhibitory control (reduced anti-saccade errors), while potentially altering response speed or precision.

Beyond these conventional measures, emerging evidence indicates that the AT1R may additionally modulate overarching behavioral adaptations, with recent studies indicating a role in the adaptation towards threat (Zika et al., 2024) and negative feedback (T. Xu et al., 2023; X. Zhou et al., 2023) Classical analyses of the anti-saccade task focus on condition-level performance (e.g., average accuracy or latency differences between pro- and anti-saccade task), however, sequential adaptations - including post-error adjustments (e.g., post-error slowing [PES], improvement in accuracy [PIA]) and stimulus switch effects⁻ provide additional critical insights into trial-by-trial dynamics of error monitoring and cognitive flexibility (Monsell, 2003; Notebaert et al., 2009). These behavioral adaptations may either reflect enhanced top-down control (Ridderinkhof et al., 2004) or bottom-up attentional responses to unexpected events (Danielmeier & Ullsperger, 2011; Vandierendonck et al., 2010). Surprisingly, despite post-error adjustments and task switching effects

having been extensively studied in the field of cognitive control, no studies have systematically examined these effects in emotional anti-saccade task nor explored the impact of pharmacological interventions on these dynamic adjustment processes. Given that the anti-saccade paradigm is well-suited to examine both post-error and post-switch behavioral adaptations, we developed a trial-history informed dynamic control framework (TIDC) to capture these dynamic adjustments and subsequently examine whether AT1R modulates the corresponding adaptation.

Finally, despite long-standing evidence for AT1R receptor expression and signaling differ between sexes (Bold & L, 1999; Y. F. Chen et al., 1992), previous studies have not found or examined sex differences in the effects of AT1R blockade on social-cognitive and affective functions (Prasad et al., 2025; X. Zhou et al., 2023).

Against this background the present pre-registered randomized placebo-controlled pharmacological eyetracking study aimed to explore the effects of a single dosage of a selective AT1R antagonist (50mg Losartan) on bottom-up and top-down attentional control, with a particular focus on their modulatory effects on social emotional processing, trial-by-trial behavioral adaptation effects, and potential sex differences. We will employ a validated emotional anti-saccade task (X. Xu et al., 2019; Zhuang, Zheng, et al., 2021), which includes social stimuli (faces expressing different emotions) and non-social stimuli (oval shapes), measuring not only traditional directional error rates and response latencies but also innovatively analyzing trial-by-trial behavioral adaptation effects. We hypothesized that transient AT1R blockade (1) will improve performance in the anti-saccade task reflecting enhanced top-down attentional control; (2) will facilitate both post-error adjustment and stimulus-switch processing, reflecting improved behavioral adaptation; (3) may exert different effects on attentional control and behavioral adaptation between males and females.

2 Method

2.1 Participants

A total of 80 healthy participants were recruited for the preregistered pharmacological eye-tracking experiment (for details, see CONSORT flowchart in **Fig. 1**). One participant was excluded due to device problems, resulting in a final sample of 79 participants (losartan [LT], n=39; placebo [PLC], n=40).

The study was approved by the local ethics committee of University of Electronic Science and Technology of China (UESTC), conducted according to the Declaration of Helsinki, and pre-registered (ClinicalTrials.gov ID: NCT06329050). All participants provided written informed consent and received monetary compensation (140 RMB).

Fig 1. CONSORT flowchart. Detailed exclusion criteria are provided in the supplementary materials.

2.2 Study Protocols

We employed a randomized, double-blind, placebo-controlled, between-subject design to examine neurocognitive effects of transient AT1R blockade using a pro- and anti-saccade tasks (**Fig. 2A**). Participants were randomly assigned to receive either a single 50-mg dose of LT or PLC, administered orally in identical capsules. Randomization was computer-generated and implemented by an independent researcher who had no direct contact with participants or experimenters.

Mood and anxiety assessments were conducted using validated Chinese versions of standardized questionnaires. Prior to drug administration, participants completed the Positive and Negative Affect Schedule (PANAS) (Watson et al., 1988), the State-Trait Anxiety Inventory (STAI) (Spielberger, 2012), and the Liebowitz Social Anxiety Scale (LSAS) (Heimberg et al., 1999) to assess baseline affective states and fear-related traits. State anxiety (STAI state subscale) was re-assessed immediately after the experiment.

Cardiovascular measurements (blood pressure and heart rate) were taken at baseline, peak drug effect (90 minutes post-administration), and post-experiment. In line with the pharmacokinetics of LT - peak plasma levels occurring at approximately 90 minutes and a terminal elimination half-life of 1.5-2.5 hours (Collister et al., 2002; Sica et al., 2005; T. Xu et al., 2022) - all experimental procedures were timed to commence during peak plasma levels.

2.3 Paradigm

The present study employed a validated anti-saccade paradigm (N. T. M. Chen et al., 2014; Zhuang et al., 2022), featuring five social-emotional facial expressions (angry, sad, happy, fearful, and neutral) from eight actors (4 male, 4 female) and eight non-social oval shapes with slight variations. To prevent affective carry-over effects, the task began with two non-social blocks (one anti-saccade and one pro-saccade block), each containing 48 trials. These were followed by 12 emotional blocks (6 anti-saccade and 6 pro-saccade blocks), with 40 trials per block (8 trials per emotion). Block order (anti- vs. pro-saccade) and trial sequence within blocks were randomized.

Each block started with a 2000ms instructional cue ("Towards" or "Away"; **Fig. 2B**), followed by a jittered fixation period (mean duration: 1500ms; range: 1000–3500ms), during which participants were instructed to maintain fixation. Subsequently, a stimulus appeared on either the left or right side of the screen for 1000ms. In "Away" blocks (anti-saccade task), participants were required to look in the direction opposite to the stimulus, while in "Towards" blocks (pro-saccade task), they were instructed to look toward the stimulus as quickly and accurately as possible. The task lasted approximately 40 minutes, with brief rest periods provided between blocks.

Fig 2. **(A)** Experimental timeline showing the measurement points and drug administration schedule. **(B)** The emotional anti-saccade paradigm and timing set including the pro-saccade (left) and anti-saccade task (right).

2.4 Data recording and processing

Eye movement data were recorded using an EyeLink 1000 Plus system (SR Research, Ottawa, Canada) sampling at 2000 Hz with a screen resolution of 1024 × 768. A chin rest positioned 57 cm from the monitor ensured standardized viewing distance and position. A 9-point calibration was

performed before each block to ensure eye-tracking data quality.

Raw eye-tracking data were preprocessed and exported using EyeLink DataViewer 3.1 (SR Research, Mississauga, Ontario, Canada). Following established procedures in saccade paradigms (Antoniades et al., 2013; Hutton & Ettinger, 2006; X. Xu et al., 2019; Zhuang, Zheng, et al., 2021), trials were excluded based on the following criteria: latencies < 70 ms or > 700 ms, saccade velocities below 30°/sec, or initial fixation deviations exceeding 2°.

2.5 Statistical Analyses

2.5.1 Initial Saccade Analyses

We analyzed initial saccades using a hierarchical approach based on established oculomotor control paradigms (Hutton & Ettinger, 2006; Luna et al., 2008). First, we examined inhibitory control through directional error rates (proportion of initial saccades opposite to the target direction) using a 2 (Treatment) × 2 (Sex) × 2 (Task) × 2 (Condition) repeated measures ANOVA. We then assessed response execution quality by analyzing both latency (time from stimulus onset to saccade initiation) and endpoint precision (Euclidean distance from landing position to target center) of the first correctly executed saccade using the same factorial design. Finally, to probe emotion-specific effects, we conducted a follow-up ANOVA replacing the binary Condition with six Stimulus types (angry, fear, sad, happy, neutral, shape) in a 2 (Treatment) × 2 (Sex) × 2 (Task) × 6 (Stimulus) design. This three-step procedure systematically evaluated performance from basic task compliance to motor execution and finally to emotional specificity.

2.5.2 Trial-history informed dynamic control (TIDC) Analyses

We analyzed trial-history effects exclusively within emotional face blocks to ensure that both stimulus switching and post-error adjustments were assessed within the domain of social information processing, thereby capturing control dynamics intrinsic to this context (Adolphs, 2009; Kanwisher et al., 1997). We focused on two key markers of dynamic control:

1). Post-error adjustments (Prev_Error: correct vs. error on trial n-1), which reflect reactive control after mistakes through enhanced cognitive engagement (Danielmeier & Ullsperger, 2011).

2). Emotion-switching costs (Stimulus_Switch: repeat vs. switch of stimulus type from trial n-1), which capture attentional flexibility when shifting between affective contexts (Monsell, 2003).

Together, these measures operationalize trial-history informed dynamic control by quantifying how prior trial outcomes and stimulus history modulate current behavior.

Generalized linear mixed models (GLMMs for error probability) and linear mixed models (LMMs for latency) are used to examine these effects. The maximal model for each outcome variable included fixed effects for Task, Treatment, Sex, Prev_Error, and Stimulus_Switch, encompassing all possible two-way and three-way interactions between these factors. The model structure was specified as:

Current_Error/Latency ~ Task × Treatment × Sex × Prev_Error × Stimulus_Switch +
(1 + Prev_Error × Stimulus_Switch || Subject)

This specification explicitly excludes higher-order (four-way and five-way) interactions for reasons of parsimony and interpretability (Brauer & Curtin, 2018; Meteyard & Davies, 2020). Random effects included random intercepts and uncorrelated slopes for the sequential effects of Prev_Error, Stimulus_Switch, and their interaction (Barr et al., 2013).

2.5.3 Software and Statistical Reporting

Statistical analyses were performed using SPSS 26 for ANOVAs and Python 3.12.5 (utilizing R's lme4 package via rpy2 interface) for mixed models (GLMM/LMM). The False Discovery Rate (FDR) procedure ($q = 0.05$) was applied to correct for multiple comparisons. Results are reported as partial eta-squared (η^2_p) for ANOVAs, odds ratios (OR) with 95% CIs for GLMMs, and standardized coefficients (β) for LMMs.

3 Results

3.1 Potential Confounders

3.1.1 Demographics, effects on anxiety and cardiovascular parameters

The LT and PLC groups showed no differences in age, mood, or personality traits at baseline (all $ps > .05$; see Table S1 for questionnaire scores). Examining effects of LT on anxiety using a 2 (Treatment: LT vs. PLC) × 2 (Sex: male, female) × 2 (Time: pre vs. post) mixed ANOVA on State Anxiety revealed significant Treatment × Time interaction ($F = 4.35$, $p = .04$, $\eta^2_p = 0.056$) (**Fig 3A**). Between-group comparison showed lower post-task anxiety scores in the LT group compared to PLC ($p = .014$, $d = 0.60$). Within-group analysis revealed significant anxiety reduction in the LT group (pre: 37.51 ± 1.10, post: 33.41 ± 1.34, $p = .004$, $dz = 0.49$) but not in the PLC group (pre: 38.17 ± 1.07, post: 38.08 ± 1.30, $p = .939$, $dz = 0.02$), suggesting an anxiolytic effect of LT. No main or interaction effects of sex were observed.

Examining cardiovascular effects using separate 2 (Treatment) × 2 (Sex) × 3 (Time: baseline, drug peak effect [80 minutes post-LT], post-task) mixed ANOVAs were conducted for systolic/diastolic blood pressure [SBP/DBP] and heart rate. Consistent with previous findings (Franklin et al., 1997), males exhibited higher resting blood pressure than females (SBP: 117.68 ± 0.88 vs. 110.57 ± 0.90 mmHg, $p < .001$; DBP: 74.58 ± 1.41 vs. 71.29 ± 1.06 mmHg, $p = .031$) (**Fig 3B**). Critically, a single dose of LT did not produce a significant blood pressure-lowering effect compared to PLC at any time point ($ps > .10$; see Table S2), which aligns with our previous studies and reflects the delayed peak cardiovascular efficacy of losartan in normotensive individuals (Reinecke et al., 2018; T. Xu et al., 2022, 2023).

3.2 Initial Saccade Performance

3.2.1 Direction Error Rate

Analysis revealed the expected main effects of Task ($F = 132.13$, $p < .001$, $\eta^2_p = 0.64$) and Condition ($F = 9.04$, $p = .004$, $\eta^2_p = 0.11$), with higher error rates in the anti-saccade compared to the pro-saccade task and in social versus nonsocial condition. This pattern replicates established findings (X. Xu et al., 2019; Zhuang et al., 2022) and validates the effectiveness of our experimental manipulation. However, no significant effects of Treatment or Sex were observed (all $ps > .05$; complete statistics are provided in the Supplementary Materials).

3.2.2 Endpoint Error

A significant four-way interaction between Treatment, Sex, Task, and Condition ($F = 5.74$,

p=.019, *η²ᵖ*=0.073) was observed on endpoint error (**Fig 3C**). In the anti-saccade task under non-social conditions, LT males demonstrated significantly larger endpoint errors than PLC males (160.07px vs 111.84px, *p* = .004), while females showed a marginal opposite trend (108.27px vs 131.54px, *p* = .056). Subsequent between-sex comparisons revealed that males in the LT group exhibited greater deviation than females (*p* = .004), whereas this pattern was reversed in the PLC group (*p* = .061). No other Task × Condition combinations showed significant treatment or sex effects (all *p*s > .26). Additional follow-up analyses that replaced the binary Condition with the six specific stimulus types did not reveal any further significant effects beyond the primary social/nonsocial distinction.

3.2.3 Latency

Analysis revealed a significant Treatment × Condition interaction (*F* = 7.51, *p* = .008, *η²ᵖ* = 0.09), with the LT group showing longer latencies than PLC in non-social conditions (*p*=.013) but not in social conditions (*p* = .59; **Fig. 3D**). Follow up 2 (Treatment) × 2 (Sex) × 2 (Task) × 6 (Stimulus) analysis revealed a significant Treatment × Sex × Stimulus interaction (*F* = 4.32, *p* = .002, *η²ᵖ* = 0.23) where LT males exhibited longer latencies specifically for shape stimuli compared to PLC males (*p* = .035), while no treatment differences were observed in females (*p* = .148).

Fig 3. Assessment of Potential Confounders and Initial Saccade Performance. (A) State anxiety scores (STAI-S) before and after the experiment in LT and PLC groups; **(B) Systolic and diastolic blood pressure** (mmHg) by sex. Data presented as raincloud plots (individual data points, probability density distributions, and box plots with quartiles and median). **(C) Endpoint precision** (pixels) in pro-saccade (left) and anti-saccade tasks (right). Pro-saccade performance showed no significant group differences. In anti-saccade under non-social conditions, males showed larger endpoint error under LT versus PLC, while females displayed the opposite pattern. Sex differences within treatments: higher endpoint error in females versus males under PLC, but lower under LT. **(D) Saccadic latency** (ms) was longer in LT versus PLC specifically under non-social conditions, with no group differences in social condition. Data in C and D shown as box plots (median, IQR, whiskers at 1.5 × IQR). Abbreviations: LT, Losartan; PLC, placebo; STAI-S, State-Trait Anxiety Inventory-State; IQR, interquartile range. **p* < .05, ***p* < .01, ****p* < .001

3.3 Trial-history Dependent Saccade Control

3.3.1 Current-trial Error Probability Modulation

Significant main effects were observed for Treatment (OR = 0.86, 95%CI [0.77, 0.96], p = .008), Task (OR = 2.09, 95%CI [1.86, 2.34], p < .001), Sex (OR = 0.84, 95%CI [0.75, 0.94], p = .003), Prev_Error (OR = 0.24, 95%CI [0.13, 0.40], p < .001) and Stimulus_Switch (OR = 0.10, 95%CI [0.08, 0.13], p < .001). Current trial error probability was lower in the LT (vs. PLC) group, males (vs. females), pro-saccade (vs. anti-saccade) tasks, post-error (vs. post-correct) trials, and stimulus switch (vs. repeat) trials (**Fig. 4A** shows raw probability distributions of prev-error and stimulus_switch).

The Task × Prev_Error × Stimulus_Switch interaction (OR = 4.14, 95%CI [1.42, 13.82], p = .013; **Fig. 4B**) revealed that in the pro-saccade task, switching produced lower error rates than repetition following both correct and error trials (ps < .001). In the anti-saccade task, switching reduced error rates following correct trials (p = .01) but increased them following errors (p < .001). Critically, stimulus repetition led to consistently lower error probabilities following error compared to correct trials (ps < .001). In contrast, switching stimuli showed no significant difference between post-error and post-correct trials (ps > .34). These findings demonstrate that an overall switch advantage under simple conditions gives way to a repetition benefit following errors.

The Treatment × Task × Prev_Error interaction (OR = 1.519, 95%CI [1.007, 2.291], p = .046; **Fig 4C**) showed enhanced post-error adjustment under LT, with lower error probability in the LT group than the PLC group following error trials in both tasks (ps < .01), no group differences following correct trials (ps > .57).

The Treatment × Task × Stimulus Switch interaction (OR = 1.52, 95%CI [1.02, 2.30], p = .047; **Fig 4D**) revealed that in the anti-saccade task, the LT group demonstrated lower error rates than the PLC group during stimulus repetition trials (p = .02), while no treatment difference was found during switching trials (p = .54) or in the pro-saccade task (ps > .13).

Treatment effects also varied among sex, as revealed by the Treatment × Sex interaction (OR = 1.31, 95%CI [1.12, 1.54], p < .001) and Treatment × Sex × Prev_Error interaction (OR = 1.386, 95%CI [1.024, 1.875], p = .034; **Fig 4E**). LT females showed consistently lower error probability than PLC females (ps < .001). In contrast, LT males showed higher error probability than PLC males following correct trials (p = .001) but comparable performance following error trials (p = .88). While males showed lower error probability than females in the PLC group (p < .001), this sex difference was not present in the LT group (p = .79).

Fig 4. Dynamic modulation of current trial error probability by trial history

(A) The probability distributions of current trial performance under different trial-history conditions.
The upper panel contrasts switch versus repeat trials, demonstrating lower error rates for switch trials (11.2%,

n=30,637) compared to repeat trials (19.5%, n=33,066). The lower panel illustrates the post-error adaptation pattern, with markedly reduced error rates following errors (9.8%, n=9,874) relative to following correct responses (16.5%, n=53,829). Notably, given the substantial disparity in trial counts between post-error and post-correct conditions (9,874 vs. 53,829), **subsequent analyses were based on estimated marginal means** to ensure appropriate weighting of this unbalanced design. **(B) Task ×Prev_Error × Stimulus Switch**: Across tasks, performance improved on repetition trials following errors. Task-specifically, pro-saccades showed better performance on switch trials regardless of previous outcome, while anti-saccades exhibited improved performance on switch trials only after correct responses but deteriorated after errors (Error bars reflect ±95% CI of the estimated marginal means; violin plots depict raw data distribution). **(C) Treatment × Task × Prev_Error**: LT reduced errors following previous errors in both saccade tasks compared to PLC. **(D) Treatment × Task × Stimulus Switch**: LT selectively reduced errors in anti-saccade repeat trials. **(E) Treatment × Sex × Previous Error**: After correct trials, LT increased errors in males but decreased errors in females versus PLC. LT females showed reduced errors regardless of previous accuracy. Error bars represent 95% confidence intervals from generalized mixed linear models. *$p<.05$, **$p<.01$, ***$p<.001$.

3.3.2 Current-trial Latency Adjustment

Significant main effects emerged for Prev_Error (β = -151.65, SE = 6.47, 95% CI [-164.33, -138.97], $p < .001$) and Stimulus_Switch (β = -224.81, SE = 2.53, 95% CI [-229.77, -219.85], $p < .001$). Current trial latencies were shorter following errors compared to correct trials (291 ms vs. 353 ms) and following stimulus switches compared to repeats (228 ms vs. 416 ms; for distributions, see **Fig. 5A**).

The Task × Prev_Error × Stimulus_Switch interaction (β = -82.53, SE = 10.10, 95% CI [-102.33, -62.73], $p < .001$; **Fig. 5B**) revealed that in pro-saccade task, responses following errors showed shorter latencies than those following correct trials during stimulus repetition ($p < .001$), but this difference was not observed during stimulus switching ($p = .44$). In anti-saccade task, responses following errors consistently showed shorter latencies than those following correct trials across both repeat and switch conditions ($ps = .001$).

The Treatment × Sex × Task interaction (β = -26.26, SE = 5.25, 95% CI [-36.54, -15.98], $p < .001$; **Fig. 5C**) showed that LT reduced latencies in females specifically during pro-saccade tasks (vs. PLC: $p = .004$), with no effects in anti-saccade tasks ($p = .21$) or in males ($ps > .54$). Sex comparisons showed that PLC males demonstrated consistently shorter latencies than PLC females across both tasks ($ps < .001$). Under LT, this male advantage persisted in anti-saccade tasks ($p = .002$) but disappeared in pro-saccade tasks ($p = .33$).

The Treatment × Sex × Stimulus_Switch interaction (β = -14.04, SE = 5.03, 95% CI [-23.89, -4.19], $p = .003$; **Fig. 5D**) revealed that LT females exhibited shorter latencies than PLC females during stimulus repetitions (436ms vs. 440ms, $p = .01$) but longer latencies during switches (255ms vs. 250ms, $p = .02$). Males showed no treatment effects ($ps > .75$) and demonstrated consistently shorter latencies than females across all conditions ($ps < .05$).

Fig 5. Dynamic modulation of current trial saccadic latency by trial history .

(A) Kernel density estimation (KDE) of saccadic latency distributions. Left panel: post-error trials show a peaked distribution around 250ms, whereas post-correct responses spread broadly between 200-600ms. Right panel: switch trials concentrate between 200-300ms, while repeat trials distribute widely around 400-600ms. **(B) Task × Prev_Error × Stimulus Switch:** Pro-saccade task showed reduced latencies following errors during stimulus repetition, with this effect disappearing during stimulus switching. Anti-saccade task demonstrated reduced latencies following errors in both stimulus repetition and switch conditions. **(C) Treatment × Sex × Task:** In pro-saccade task, LT females showed reduced latencies compared to PLC females, while PLC males performed faster than PLC females. In anti-saccade task, males showed consistently shorter latencies than females, with no treatment difference. **(D) Treatment × Sex × Stimulus_Switch:** Under stimulus repetition, LT females exhibited reduced latencies versus PLC females. During stimulus switching, female participants showed increased latencies compared to males. Error bars represent 95% confidence intervals. *$p<.05$, **$p<.01$, ***$p<.001$.

4 Discussion

Our pharmacological eye-tracking study employed an emotional anti-saccade task to demonstrate an anxiolytic potential of transient angiotensin II receptor blockade via losartan and showed that it modulates both top-down goal-directed attention and bottom-up stimulus-driven processing with partially sex-dependent effects. By integrating analyses of initial oculomotor responses with trial-history informed dynamic control (TIDC), we demonstrate that losartan induces a sexually dimorphic reconfiguration of attentional processes, with findings highlighting that:

(1) Independent of treatment, we observed a general "post-error repetition benefit" where performance improved on repetition trials following errors, and a "task-dependent switch effect", whereas switching enhanced performance in the pro-saccade task regardless of prior outcome, which together led to improved performance in the anti-saccade specifically after correct trials yet impaired performance following errors.

(2) Losartan enhanced the general utilization of contextual information by reducing error probabilities on both trials following an error and stimulus repetition trials.

(3)   Most critically, losartan reconfigured attentional processing in a sex-divergent manner. In females, it induced a shift that refined motor execution (reduced endpoint error) and enhanced flexibility (e.g., adaptive latency adjustment). In males, losartan induced a induced motor precision deficits (increased endpoint error) and reduced cognitive flexibility (e.g., elevated post-correct errors). This may reflect a failure to disengage from effortful control when it was not beneficial.

4.1 Context-Sensitive Adaptive Control

Our trial-history informed dynamic control (TIDC) analysis revealed a core principle of adaptive control independent of treatment - a context-sensitive arbitration between cognitive stability and flexibility.

First, we observed a robust "post-error repetition benefit"—higher accuracy on repetition trials following errors. This reflects a strategic shift toward cognitive stability after failures, likely serving to re-establish task set stability and prevent consecutive errors, a process associated with error detection in the anterior cingulate cortex (Botvinick et al., 2004; Danielmeier & Ullsperger, 2011).

Second, we found a "task-dependent switch effect", demonstrating a nuanced gating of cognitive flexibility. In the low-demand pro-saccade task, switching conferred a general advantage, indicating a default bias toward exploratory processing. Conversely, in the cognitively demanding anti-saccade task—which heavily relies on prefrontal control networks (McDowell et al., 2008)—the system strategically modulated flexibility: switching was beneficial after correct trials when control was robust, but led to reduce performance after errors.

This pattern may reflect a dynamic and context-sensitive allocation of control accounting for both, current task demands and recent performance history (Musslick & Cohen, 2021; Shenhav et al., 2016), and may optimize behavior via a continuous stability-flexibility trade-off.

4.2 Baseline Performance in the PLC group

Analysis of baseline (PLC) performance, starting with the initial saccade (Coe & Munoz, 2017) revealed that males generated significantly more precise initial saccades (i.e., smaller endpoint error) in the anti-saccade task as compared to females, in the context of comparable latencies. The processing differences extended further to global task performance, such that when considering all saccades (Ethier et al., 2008), males in the PLC group demonstrated lower current error probabilities and shorter latencies across trials compared to females in the PLC group. This pattern may reflect a higher baseline level of global processing efficiency in males. Crucially, this advantage remained stable and was not modulated by trial history (e.g., previous error or stimulus switch), suggesting it may reflect differences in automated and rapid execution rather than from more effortful, supervisory control (Hutton & Ettinger, 2006).

4.3 Effects of Losartan on Multiple Dimension

With respect to treatment effects losartan reduced anxiety across the sexes, such that the treatment group reported reduced anxiety over the course of the experiment. These general effects of losartan on subjective experience were accompanied by sexually dimorphic effects on attentional processing strategy.

Specifically, analysis of the initial saccade, a probe of rapid sensorimotor processing, revealed that losartan exerts opposing effects on automatic processes in men and women. In males, the drug disrupted automatic processing, as reflected by increased endpoint errors and latency of first correctly executed saccade. This pattern may reflect increasing costs of enhanced cognitive supervision on automatic subcortical-motor processing. Conversely, in females a significant decrease in endpoint error was observed. We hypothesize that in women, characterized by a more extensive prefrontal recruitment during cognitive control, as observed in previous studies (Bell et al., 2006), transient AT1R blockade may have promoted a calibration of the initial motor command (Hosp et al., 2011), thereby enhancing its precision.

Moreover, losartan enhanced the use of contextual information from previous trials to guide current behavior, evidenced by a marked reduction in error probabilities on both post-error and stimulus repetition trials in the anti-saccade task. This suggests that transient AT1R blockade may facilitate context-dependent adaptive control which are supported by prefrontal networks and their interaction with subcortical affective and motor processing regions, including the anterior cingulate and lateral prefrontal cortex (Botvinick et al., 2004; Cools et al., 2011; Li et al., 2020; Zhuang et al., 2023; Zhuang, Xu, et al., 2021). Notably, these adaptive effects of losartan were expressed in a sexually dimorphic manner in an interaction with baseline differences. Following correct trials—when demand for high control is low—women on losartan maintained low error probabilities, effectively sustaining control, while men on losartan however, showed elevated current error probabilities following a correct trial, indicating a failure to disengage from the previous trial and reflecting flexibility. Furthermore, women on losartan exhibited faster responses on stimulus repeats and slower responses on switches, indicating strategic allocation of attentional resources. Losartan-treated men showed no such differential adjustment, suggesting more rigid behavioral adaption.

In summary, our findings indicate an implication of the RAS systems in controlled and adaptive attention allocation in the context of anxiolytic effects. The shift to a different processing mode interacts with baseline differences between men and women, leading to improved performance in females, probably via enhanced basic motor commands and higher-order adaptive processing, while disrupting performance in men and reducing their efficient automatic processing. Consequently, transient AT1R blockade leads to a sex-specific reconfiguration of adaptative attentional processing which evolves in interaction with baseline processing differences.

4.4 The Role of RAS in Attention and Clinical Implications

Our findings advance understanding of the renin-angiotensin system in attentional processing, such that AT1R blockade via losartan modulates key facets of attentional control, providing evidence for the role of the central RAS in attention regulation, beyond its classical role in cardiovascular regulation. This supports the concept of an active "brain-RAS" involved in cognitive functions (Labandeira-García et al., 2014; Wright & Harding, 2010; T. Xu et al., 2025).

Second, the sex-dependent effects of losartan indicate that future studies on the clinical application need to account for sex-specific effects and may reflect that the RAS exerts its impact on cognition in interaction with other hormonal and neurotransmitter systems (see also T. Xu et al., 2024). The present findings may indicate a particular promising therapeutic effect for women with disorders characterized by impaired cognitive performance, e.g. Alzheimer's disease, ADHD, and anxiety disorders (Carnovale et al., 2023; Saavedra, 2012).

Methodologically, our dual-level analytical approach combining trial-averaged and trial-wise data, allowed detection of these nuanced effects, which would be missed in traditional analyses. Incorporating emotional stimuli further revealed how RAS modulation interacts with affective functions and may underpin the anxiolytic effects reported for AT1R antagonists (Reinecke et al., 2018; T. Xu et al., 2022, 2023).

Results have to be interpreted in the context of limitations, including single-dose design, which may not generalize to chronic administration and a lack of hormonal profiling in female participants. Despite these limitations, our findings suggest that the sex-dependent cognitive effects of AT1R antagonists like losartan could offer therapeutic opportunities for hypertensive patients who also have cognitive impairments. Moreover, the observed sex-specific effects advocate for sex-stratified dosing strategies or alternative medication selection based on individual cognitive profiles.

In conclusion, this study establishes the renin-angiotensin system (RAS) as a key modulator of attentional control, with multidimensional effects significantly moderated by sex. Our findings that AT1R antagonists can improve attentional control—particularly in processing emotional information and enhancing behavioral adaptation—may present the basis for developing novel therapeutic strategies for mental disorders characterized by such deficits, such as anxiety, depression, and PTSD. The results not only enhance the theoretical understanding of brain-RAS function but also support the development of personalized treatments for both cardiovascular and mental disorders.

Funding

The project has been supported by the Health and Medical Research Fund Hong Kong (HMRF, 23243971), Ministry of Science and Technology of China (STI 2030 – Major Projects 2022ZD0208500), the University of Hong Kong seed funding and start-up schemes (2407102536; 2402101713).

Reference

Adolphs, R. (2009). The social brain: Neural basis of social knowledge. *Annual Review of Psychology*, *60*, 693–716. https://doi.org/10.1146/annurev.psych.60.110707.163514

Ali, N. H., Al-Kuraishy, H. M., Al-Gareeb, A. I., Albuhadily, A. K., Hamad, R. S., Alexiou, A., Papadakis, M., Saad, H. M., & Batiha, G. E.-S. (2024). Role of brain renin-angiotensin system in depression: A new perspective. *CNS Neuroscience & Therapeutics*, *30*(4), e14525. https://doi.org/10.1111/cns.14525

Antoniades, C., Ettinger, U., Gaymard, B., Gilchrist, I., Kristjánsson, A., Kennard, C., John Leigh, R., Noorani, I., Pouget, P., Smyrnis, N., Tarnowski, A., Zee, D. S., & Carpenter, R. H. S. (2013). An internationally standardised antisaccade protocol. *Vision Research*, *84*, 1–5. https://doi.org/10.1016/j.visres.2013.02.007

Barr, D. J., Levy, R., Scheepers, C., & Tily, H. J. (2013). Random effects structure for confirmatory hypothesis testing: Keep it maximal. *Journal of Memory and Language*, *68*(3). https://doi.org/10.1016/j.jml.2012.11.001

Barthold, D., Joyce, G., Wharton, W., Kehoe, P., & Zissimopoulos, J. (2018). The association of

multiple anti-hypertensive medication classes with alzheimer's disease incidence across sex, race, and ethnicity. *PloS One*, *13*(11), e0206705. https://doi.org/10.1371/journal.pone.0206705

Bell, E. C., Willson, M. C., Wilman, A. H., Dave, S., & Silverstone, P. H. (2006). Males and females differ in brain activation during cognitive tasks. *NeuroImage*, *30*(2), 529–538. https://doi.org/10.1016/j.neuroimage.2005.09.049

Benicky, J., Sánchez-Lemus, E., Honda, M., Pang, T., Orecna, M., Wang, J., Leng, Y., Chuang, D.-M., & Saavedra, J. M. (2011). Angiotensin II AT1 receptor blockade ameliorates brain inflammation. *Neuropsychopharmacology: Official Publication of the American College of Neuropsychopharmacology*, *36*(4), 857–870. https://doi.org/10.1038/npp.2010.225

Bishop, S. J. (2009). Trait anxiety and impoverished prefrontal control of attention. *Nature Neuroscience*, *12*(1), 92–98. https://doi.org/10.1038/nn.2242

Bold K., & L M. (1999). Estrogen, natriuretic peptides and the renin–angiotensin system. *Cardiovascular Research*, *41*(3), 524–531. https://doi.org/10.1016/S0008-6363(98)00324-1

Botvinick, M. M., Cohen, J. D., & Carter, C. S. (2004). Conflict monitoring and anterior cingulate cortex: An update. *Trends in Cognitive Sciences*, *8*(12), 539–546. https://doi.org/10.1016/j.tics.2004.10.003

Brauer, M., & Curtin, J. J. (2018). Linear mixed-effects models and the analysis of nonindependent data: A unified framework to analyze categorical and continuous independent variables that vary within-subjects and/or within-items. *Psychological Methods*, *23*(3), 389–411. https://doi.org/10.1037/met0000159

Cameron, I. G. M., Wallace, D. L., Al-Zughoul, A., Kayser, A. S., & D'Esposito, M. (2018). Effects of tolcapone and bromocriptine on cognitive stability and flexibility. *Psychopharmacology*, *235*(4), 1295–1305. https://doi.org/10.1007/s00213-018-4845-4

Carnovale, C., Perrotta, C., Baldelli, S., Cattaneo, D., Montrasio, C., Barbieri, S. S., Pompilio, G., Vantaggiato, C., Clementi, E., & Pozzi, M. (2023). Antihypertensive drugs and brain function: Mechanisms underlying therapeutically beneficial and harmful neuropsychiatric effects. *Cardiovascular Research*, *119*(3), 647–667. https://doi.org/10.1093/cvr/cvac110

Chen, N. T. M., Clarke, P. J. F., Watson, T. L., MacLeod, C., & Guastella, A. J. (2014). Biased saccadic responses to emotional stimuli in anxiety: An antisaccade study. *PLOS ONE*, *9*(2), e86474. https://doi.org/10.1371/journal.pone.0086474

Chen, Y. F., Naftilan, A. J., & Oparil, S. (1992). Androgen-dependent angiotensinogen and renin messenger RNA expression in hypertensive rats. *Hypertension (Dallas, Tex.: 1979)*, *19*(5), 456–463. https://doi.org/10.1161/01.hyp.19.5.456

Chrissobolis, S., Luu, A. N., Waldschmidt, R. A., Yoakum, M. E., & D'Souza, M. S. (2020). Targeting the renin angiotensin system for the treatment of anxiety and depression. *Pharmacology, Biochemistry, and Behavior*, *199*, 173063. https://doi.org/10.1016/j.pbb.2020.173063

Cisler, J. M., & Koster, E. H. W. (2010). Mechanisms of attentional biases towards threat in anxiety disorders: An integrative review. *Clinical Psychology Review*, *30*(2), 203–216. https://doi.org/10.1016/j.cpr.2009.11.003

Coe, B. C., & Munoz, D. P. (2017). Mechanisms of saccade suppression revealed in the anti-saccade task. *Philosophical Transactions of the Royal Society B: Biological Sciences*, *372*(1718), 20160192. https://doi.org/10.1098/rstb.2016.0192

Collister, J. P., Soucheray, S. L., & Osborn, J. W. (2002). Chronic hypotensive effects of losartan are not dependent on the actions of angiotensin II at AT 2 receptors. *Journal of Cardiovascular*

Pharmacology, *39*(1), 107–116. https://doi.org/10.1097/00005344-200201000-00012

Danielmeier, C., & Ullsperger, M. (2011). Post-error adjustments. *Frontiers in Psychology*, *2*. https://doi.org/10.3389/fpsyg.2011.00233

Diamond, A. (2013). Executive functions. *Annual Review of Psychology*, *64*(Volume 64, 2013), 135–168. https://doi.org/10.1146/annurev-psych-113011-143750

Duchemin, S., Belanger, E., Wu, R., Ferland, G., & Girouard, H. (2013). Chronic perfusion of angiotensin II causes cognitive dysfunctions and anxiety in mice. *Physiology & Behavior*, *109*, 63–68. https://doi.org/10.1016/j.physbeh.2012.10.005

Ethier, V., Zee, D. S., & Shadmehr, R. (2008). Spontaneous recovery of motor memory during saccade adaptation. *Journal of Neurophysiology*, *99*(5), 2577–2583. https://doi.org/10.1152/jn.00015.2008

Feng, C., Becker, B., Huang, W., Wu, X., Eickhoff, S. B., & Chen, T. (2018). Neural substrates of the emotion-word and emotional counting stroop tasks in healthy and clinical populations: A meta-analysis of functional brain imaging studies. *NeuroImage*, *173*, 258–274. https://doi.org/10.1016/j.neuroimage.2018.02.023

Gao, N., Wang, H., Xu, X., Yang, Z., & Zhang, T. (2021). Angiotensin II induces cognitive decline and anxiety-like behavior via disturbing pattern of theta-gamma oscillations. *Brain Research Bulletin*, *174*, 84–91. https://doi.org/10.1016/j.brainresbull.2021.06.002

Han, M., Dong, W., Fu, K., Wang, J., Xu, Y., Zheng, Y., Kendrick, K. M., Stefania, F., Xu, T., Yao, D., & Becker, B. (2025). *Vasopressin and angiotensin II differentially modulate human fear response dynamics to looming threats* (p. 2025.05.18.25327885). medRxiv. https://doi.org/10.1101/2025.05.18.25327885

Heimberg, R. G., Horner, K. J., Juster, H. R., Safren, S. A., Brown, E. J., Schneier, F. R., & Liebowitz, M. R. (1999). Psychometric properties of the liebowitz social anxiety scale. *Psychological Medicine*, *29*(1), 199–212. https://doi.org/10.1017/S0033291798007879

Hosp, J. A., Pekanovic, A., Rioult-Pedotti, M. S., & Luft, A. R. (2011). Dopaminergic projections from midbrain to primary motor cortex mediate motor skill learning. *Journal of Neuroscience*, *31*(7), 2481–2487. https://doi.org/10.1523/JNEUROSCI.5411-10.2011

Hutton, S. B., & Ettinger, U. (2006). The antisaccade task as a research tool in psychopathology: A critical review. *Psychophysiology*, *43*(3), 302–313. https://doi.org/10.1111/j.1469-8986.2006.00403.x

Jackson, L., Eldahshan, W., Fagan, S. C., & Ergul, A. (2018). Within the brain: The renin angiotensin system. *International Journal of Molecular Sciences*, *19*(3), 876. https://doi.org/10.3390/ijms19030876

Kanaan, D., & Moacdieh, N. M. (2022). Eye tracking to evaluate the effects of interruptions and workload in a complex task. *Human Factors*, *64*(7), 1168–1180. https://doi.org/10.1177/0018720821990487

Kang, S., Kim, J., Yang, J. S., Jeon, Y. J., Lee, H.-H., Suglia, S. F., Tsai, A. C., Kang, J. I., & Jung, S. J. (2024). Use of renin-angiotensin system blockers and posttraumatic stress disorder risk in the UK biobank: A retrospective cohort study. *BMC Medicine*, *22*(1), 489. https://doi.org/10.1186/s12916-024-03704-5

Kanwisher, N., McDermott, J., & Chun, M. M. (1997). The fusiform face area: A module in human extrastriate cortex specialized for face perception. *The Journal of Neuroscience: The Official Journal of the Society for Neuroscience*, *17*(11), 4302–4311.

https://doi.org/10.1523/JNEUROSCI.17-11-04302.1997

Khoury, N. M., Marvar, P. J., Gillespie, C. F., Wingo, A., Schwartz, A., Bradley, B., Kramer, M., & Ressler, K. J. (2012). The renin-angiotensin pathway in posttraumatic stress disorder: Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers are associated with fewer traumatic stress symptoms. *The Journal of Clinical Psychiatry*, *73*(6), 849–855. https://doi.org/10.4088/JCP.11m07316

Labandeira-García, J. L., Garrido-Gil, P., Rodriguez-Pallares, J., Valenzuela, R., Borrajo, A., & Rodríguez-Perez, A. I. (2014). Brain renin-angiotensin system and dopaminergic cell vulnerability. *Frontiers in Neuroanatomy*, *8*. https://doi.org/10.3389/fnana.2014.00067

Li, J., Yang, X., Zhou, F., Liu, C., Wei, Z., Xin, F., Daumann, B., Daumann, J., Kendrick, K. M., & Becker, B. (2020). Modafinil enhances cognitive, but not emotional conflict processing via enhanced inferior frontal gyrus activation and its communication with the dorsomedial prefrontal cortex. *Neuropsychopharmacology: Official Publication of the American College of Neuropsychopharmacology*, *45*(6), 1026–1033. https://doi.org/10.1038/s41386-020-0625-z

Luna, B., Velanova, K., & Geier, C. F. (2008). Development of eye-movement control. *Brain and Cognition*, *68*(3), 293–308. https://doi.org/10.1016/j.bandc.2008.08.019

McDowell, J. E., Dyckman, K. A., Austin, B. P., & Clementz, B. A. (2008). Neurophysiology and neuroanatomy of reflexive and volitional saccades: Evidence from studies of humans. *Brain and Cognition*, *68*(3), 255–270. https://doi.org/10.1016/j.bandc.2008.08.016

Meteyard, L., & Davies, R. A. I. (2020). Best practice guidance for linear mixed-effects models in psychological science. *Journal of Memory and Language*, *112*, 104092. https://doi.org/10.1016/j.jml.2020.104092

Monsell, S. (2003). Task switching. *Trends in Cognitive Sciences*, *7*(3), 134–140. https://doi.org/10.1016/s1364-6613(03)00028-7

Munoz, D. P., & Everling, S. (2004). Look away: The anti-saccade task and the voluntary control of eye movement. *Nature Reviews Neuroscience*, *5*(3), 218–228. https://doi.org/10.1038/nrn1345

Musslick, S., & Cohen, J. D. (2021). Rationalizing constraints on the capacity for cognitive control. *Trends in Cognitive Sciences*, *25*(9), 757–775. https://doi.org/10.1016/j.tics.2021.06.001

Noorani, I., & Carpenter, R. H. S. (2016). The LATER model of reaction time and decision. *Neuroscience & Biobehavioral Reviews*, *64*, 229–251. https://doi.org/10.1016/j.neubiorev.2016.02.018

Notebaert, W., Houtman, F., Opstal, F. V., Gevers, W., Fias, W., & Verguts, T. (2009). Post-error slowing: An orienting account. *Cognition*, *111*(2), 275–279. https://doi.org/10.1016/j.cognition.2009.02.002

Peers, P. V., & Lawrence, A. D. (2009). Attentional control of emotional distraction in rapid serial visual presentation. *Emotion*, *9*(1), 140–145. https://doi.org/10.1037/a0014507

Prasad, D., Shkreli, L., De Giorgi, R., Costi, S., & Reinecke, A. (2025). Acute angiotensin receptor blockade and mnemonic discrimination in healthy participants. *Journal of Affective Disorders*, *375*, 293–296. https://doi.org/10.1016/j.jad.2025.01.119

Reinecke, A., Browning, M., Klein Breteler, J., Kappelmann, N., Ressler, K. J., Harmer, C. J., & Craske, M. G. (2018). Angiotensin regulation of amygdala response to threat in high-trait-anxiety individuals. *Biological Psychiatry. Cognitive Neuroscience and Neuroimaging*, *3*(10), 826–835. https://doi.org/10.1016/j.bpsc.2018.05.007

Saavedra J. M. (2012). Angiotensin II AT1 receptor blockers as treatments for inflammatory brain

disorders. *Clinical Science*, *123*(10), 567–590. https://doi.org/10.1042/CS20120078

Seligowski, A. V., Duffy, L. A., Merker, J. B., Michopoulos, V., Gillespie, C. F., Marvar, P. J., Stein, M. B., & Ressler, K. J. (2021). The renin-angiotensin system in PTSD: A replication and extension. *Neuropsychopharmacology: Official Publication of the American College of Neuropsychopharmacology*, *46*(4), 750–755. https://doi.org/10.1038/s41386-020-00923-1

Sharifi, F., Reisi, P., & Malek, M. (2019). Angiotensin 1 receptor antagonist attenuates acute kidney injury-induced cognitive impairment and synaptic plasticity via modulating hippocampal oxidative stress. *Life Sciences*, *234*, 116775. https://doi.org/10.1016/j.lfs.2019.116775

Shenhav, A., Cohen, J. D., & Botvinick, M. M. (2016). Dorsal anterior cingulate cortex and the value of control. *Nature Neuroscience*, *19*(10), 1286–1291. https://doi.org/10.1038/nn.4384

Sica, D. A., Gehr, T. W. B., & Ghosh, S. (2005). Clinical pharmacokinetics of losartan. *Clinical Pharmacokinetics*, *44*(8), 797–814. https://doi.org/10.2165/00003088-200544080-00003

Spielberger, C. D. (2012). *State-trait anxiety inventory for adults* [Dataset]. https://doi.org/10.1037/t06496-000

Swiercz, A. P., Iyer, L., Yu, Z., Edwards, A., Prashant, N. M., Nguyen, B. N., Horvath, A., & Marvar, P. J. (2020). Evaluation of an angiotensin type 1 receptor blocker on the reconsolidation of fear memory. *Translational Psychiatry*, *10*(1), 363. https://doi.org/10.1038/s41398-020-01043-6

Vandierendonck, A., Liefooghe, B., & Verbruggen, F. (2010). Task switching: Interplay of reconfiguration and interference control. *Psychological Bulletin*, *136*(4), 601–626. https://doi.org/10.1037/a0019791

Vetter, R. S. (2012). Calling all arachnophobic entomologists: A request for information. *American Entomologist*, *58*(4), 199–201. https://doi.org/10.1093/ae/58.4.199

Watson, D., Clark, L. A., & Tellegen, A. (1988). Development and validation of brief measures of positive and negative affect: The PANAS scales. *Journal of Personality and Social Psychology*, *54*(6), 1063–1070. https://doi.org/10.1037/0022-3514.54.6.1063

Wright, J. W., & Harding, J. W. (2010). The brain RAS and alzheimer's disease. *Experimental Neurology*, *223*(2), 326–333. https://doi.org/10.1016/j.expneurol.2009.09.012

Xu, T., Chen, Z., Zhou, X., Wang, L., Zhou, F., Yao, D., Zhou, B., & Becker, B. (2024). The central renin–angiotensin system: A genetic pathway, functional decoding, and selective target engagement characterization in humans. *Proceedings of the National Academy of Sciences*, *121*(8), e2306936121. https://doi.org/10.1073/pnas.2306936121

Xu, T., Fu, K., Yao, D., Ma, C., & Becker, B. (2025). *The brain renin angiotensin system: A novel precision target for neurofunctional symptom regulation*. OSF. https://doi.org/10.31234/osf.io/fbcv4_v1

Xu, T., Zhou, X., Jiao, G., Zeng, Y., Zhao, W., Li, J., Yu, F., Zhou, F., Yao, S., & Becker, B. (2022). Angiotensin antagonist inhibits preferential negative memory encoding via decreasing hippocampus activation and its coupling with the amygdala. *Biological Psychiatry: Cognitive Neuroscience and Neuroimaging*, *7*(10), 970–978. https://doi.org/10.1016/j.bpsc.2022.05.007

Xu, T., Zhou, X., Kanen, J. W., Wang, L., Li, J., Chen, Z., Zhang, R., Jiao, G., Zhou, F., Zhao, W., Yao, S., & Becker, B. (2023). Angiotensin blockade enhances motivational reward learning via enhancing striatal prediction error signaling and frontostriatal communication. *Molecular Psychiatry*, *28*(4), 1692–1702. https://doi.org/10.1038/s41380-023-02001-6

Xu, X., Li, J., Chen, Z., Kendrick, K. M., & Becker, B. (2019). Oxytocin reduces top-down control of attention by increasing bottom-up attention allocation to social but not non-social

stimuli—A randomized controlled trial. *Psychoneuroendocrinology*, *108*, 62–69. https://doi.org/10.1016/j.psyneuen.2019.06.004

Yang, C., He, L., Liu, Y., Lin, Z., Luo, L., & Gao, S. (2023). Anti-saccades reveal impaired attention control over negative social evaluation in individuals with depressive symptoms. *Journal of Psychiatric Research*, *165*, 64–69. https://doi.org/10.1016/j.jpsychires.2023.07.016

Zhang, R., Zhao, W., Qi, Z., Xu, T., Zhou, F., & Becker, B. (2023). Angiotensin II regulates the neural expression of subjective fear in humans: A precision pharmaco-neuroimaging approach. *Biological Psychiatry. Cognitive Neuroscience and Neuroimaging*, *8*(3), 262–270. https://doi.org/10.1016/j.bpsc.2022.09.008

Zhou, F., Geng, Y., Xin, F., Li, J., Feng, P., Liu, C., Zhao, W., Feng, T., Guastella, A. J., Ebstein, R. P., Kendrick, K. M., & Becker, B. (2019). Human extinction learning is accelerated by an angiotensin antagonist via ventromedial prefrontal cortex and its connections with basolateral amygdala. *Biological Psychiatry*, *86*(12), 910–920. https://doi.org/10.1016/j.biopsych.2019.07.007

Zhou, X., Xu, T., Zeng, Y., Zhang, R., Qi, Z., Zhao, W., Kendrick, K. M., & Becker, B. (2023). The angiotensin antagonist losartan modulates social reward motivation and punishment sensitivity via modulating midbrain-striato-frontal circuits. *The Journal of Neuroscience*, *43*(3), 472–483. https://doi.org/10.1523/JNEUROSCI.1114-22.2022

Zhuang, Q., Qiao, L., Xu, L., Yao, S., Chen, S., Zheng, X., Li, J., Fu, M., Li, K., Vatansever, D., Ferraro, S., Kendrick, K. M., & Becker, B. (2023). The right inferior frontal gyrus as pivotal node and effective regulator of the basal ganglia-thalamocortical response inhibition circuit. *Psychoradiology*, *3*, kkad016. https://doi.org/10.1093/psyrad/kkad016

Zhuang, Q., Xu, L., Zhou, F., Yao, S., Zheng, X., Zhou, X., Li, J., Xu, X., Fu, M., Li, K., Vatansever, D., Kendrick, K. M., & Becker, B. (2021). Segregating domain-general from emotional context-specific inhibitory control systems—Ventral striatum and orbitofrontal cortex serve as emotion-cognition integration hubs. *NeuroImage*, *238*, 118269. https://doi.org/10.1016/j.neuroimage.2021.118269

Zhuang, Q., Zheng, X., Becker, B., Lei, W., Xu, X., & Kendrick, K. M. (2021). Intranasal vasopressin like oxytocin increases social attention by influencing top-down control, but additionally enhances bottom-up control. *Psychoneuroendocrinology*, *133*, 105412. https://doi.org/10.1016/j.psyneuen.2021.105412

Zhuang, Q., Zheng, X., Yao, S., Zhao, W., Becker, B., Xu, X., & Kendrick, K. M. (2022). Oral administration of oxytocin, like intranasal administration, decreases top-down social attention. *International Journal of Neuropsychopharmacology*, *25*(11), 912–923. https://doi.org/10.1093/ijnp/pyac059

Zika, O., Appel, J., Klinge, C., Shkreli, L., Browning, M., Wiech, K., & Reinecke, A. (2024). Reduction of aversive learning rates in pavlovian conditioning by angiotensin II antagonist losartan: A randomized controlled trial. *Biological Psychiatry*, *96*(4), 247–255. https://doi.org/10.1016/j.biopsych.2024.01.020